Glioblastoma remains as the most common and aggressive malignant brain tumor, standing
with a poor prognosis and treatment prospective. Despite the aggressive standard care …

Glioblastoma (GBM) stands out as the most common, aggressive form of primary malignant
brain tumor conferring a devastatingly poor prognosis. Despite aggressive standard-of-care …

Glioblastoma (GBM) is the most common malignant brain tumor. Despite multimodality
treatment with surgical resection, radiation therapy, chemotherapy, and tumor treating fields …

Introduction Glioblastoma is a very aggressive cancer with dismal prognosis despite
standard of care including surgical resection, radiation therapy, and chemotherapy. There is …

Glioblastoma multiforme (GBM) is the most common and aggressive malignant brain tumor
of the central nervous system and has a very poor prognosis. The current standard of care …

Glioblastoma (GBM) is characterized by aggressive growth and high rates of recurrence.
Despite the advancements in conventional therapies, the prognosis for GBM patients …

Simple Summary Glioblastoma is the most frequent and the most aggressive brain tumor.
Even with the most current treatment, its prognosis remains dismal. Immunotherapies, novel …

Simple Summary Prognosis for glioblastoma patients remains poor despite the current
standard of care treatments. More recent investigations have focused on immunotherapy …

Abstract Purpose of Review This review seeks to inform oncology clinicians and researchers
about the development of novel immunotherapies for the treatment of glioblastoma. An …

Glioblastoma is a highly lethal brain cancer with a median survival rate of less than 15
months when treated with the current standard of care, which consists of surgery …